Circular Genomics to Present Groundbreaking Blood Biomarkers for Alzheimer's Disease at CTAD 2025
In an exciting announcement, Circular Genomics, Inc. is set to present novel findings at the upcoming CTAD 2025 conference, spotlighting circular RNAs (circRNAs) as a revolutionary class of blood-based biomarkers for Alzheimer’s Disease (AD). This research aims to transform the landscape of AD diagnostics and early intervention, promising to shift the focus from late-stage assessments to proactive, early-stage identification of the disease.
Scheduled for December 3, 2025, in San Diego, CA, the presentation will delve into the potential of the proprietary circRNA biomarker platform developed by Circular Genomics. Dr. Nikolaos Mellios, the company’s Chief Scientific Officer, emphasized the fundamental importance of this research, stating that circRNAs, as brain-derived and highly stable molecules, provide unprecedented insights into the biological pathways disrupted by Alzheimer’s.
Circular RNAs are unique non-coding RNAs, abundant in the brain, and have shown to be significantly dysregulated in various neurodegenerative disorders. They stand out from traditional linear RNA or protein biomarkers due to their stability, making them ideal candidates for blood-based assays. CircRNAs are intricately involved in crucial biological processes such as neuroinflammation, oxidative stress response, synaptic function, and amyloid/tau pathology—all central to Alzheimer’s biology. This grants circRNAs a molecular profile that could revolutionize AD diagnosis, allowing for the identification of patients in the early stages of the disease.
During the CTAD presentation, the Circular Genomics team will share insights gleaned from a well-characterized clinical cohort of AD patients. Key elements of the presentation will include:
1. Prediction models evaluating clinical status in correlation with CSF, Amyloid PET, and plasma biomarker positivity.
2. Evidence that circRNA signatures can predict who may progress from being cognitively normal to symptomatic AD patients.
3. The specificity of circRNA profiles for AD dementia versus other non-AD forms of dementia.
This work highlights the promising collaboration with renowned researchers, including Dr. Carlos Cruchaga, which has led to the identification of a robust circRNA biomarker signature that excels in detecting Alzheimer’s across its entire continuum. Mellios expresses optimism about this groundbreaking research, noting that it supports a transformative paradigm shift in early AD detection.
For physicians, these developments mean a new capability to detect Alzheimer’s symptoms well before they manifest, enabling earlier and more effective interventions. The precision provided by circRNA assessments allows for tailored, patient-centric approaches to care, fundamentally altering how Alzheimer's disease management and treatment are approached.
As Circular Genomics continues to lead the way in developing cutting-edge solutions that leverage circRNAs for precision medicine, the healthcare community is poised to benefit greatly. These breakthroughs promise not just to enhance diagnostic accuracy but also to provide much-needed hope for effective interventions in one of the most challenging neurological disorders.
Circular Genomics calls for those interested in advancing understanding of Alzheimer's to engage with their presentation at CTAD 2025, as this research signifies a pivotal moment in the journey towards improving diagnosis and treatment strategies for Alzheimer’s Disease.
Scheduled for December 3, 2025, in San Diego, CA, the presentation will delve into the potential of the proprietary circRNA biomarker platform developed by Circular Genomics. Dr. Nikolaos Mellios, the company’s Chief Scientific Officer, emphasized the fundamental importance of this research, stating that circRNAs, as brain-derived and highly stable molecules, provide unprecedented insights into the biological pathways disrupted by Alzheimer’s.
Understanding circRNAs
Circular RNAs are unique non-coding RNAs, abundant in the brain, and have shown to be significantly dysregulated in various neurodegenerative disorders. They stand out from traditional linear RNA or protein biomarkers due to their stability, making them ideal candidates for blood-based assays. CircRNAs are intricately involved in crucial biological processes such as neuroinflammation, oxidative stress response, synaptic function, and amyloid/tau pathology—all central to Alzheimer’s biology. This grants circRNAs a molecular profile that could revolutionize AD diagnosis, allowing for the identification of patients in the early stages of the disease.
The Presentation Highlights
During the CTAD presentation, the Circular Genomics team will share insights gleaned from a well-characterized clinical cohort of AD patients. Key elements of the presentation will include:
1. Prediction models evaluating clinical status in correlation with CSF, Amyloid PET, and plasma biomarker positivity.
2. Evidence that circRNA signatures can predict who may progress from being cognitively normal to symptomatic AD patients.
3. The specificity of circRNA profiles for AD dementia versus other non-AD forms of dementia.
This work highlights the promising collaboration with renowned researchers, including Dr. Carlos Cruchaga, which has led to the identification of a robust circRNA biomarker signature that excels in detecting Alzheimer’s across its entire continuum. Mellios expresses optimism about this groundbreaking research, noting that it supports a transformative paradigm shift in early AD detection.
A New Era in Alzheimer's Care
For physicians, these developments mean a new capability to detect Alzheimer’s symptoms well before they manifest, enabling earlier and more effective interventions. The precision provided by circRNA assessments allows for tailored, patient-centric approaches to care, fundamentally altering how Alzheimer's disease management and treatment are approached.
As Circular Genomics continues to lead the way in developing cutting-edge solutions that leverage circRNAs for precision medicine, the healthcare community is poised to benefit greatly. These breakthroughs promise not just to enhance diagnostic accuracy but also to provide much-needed hope for effective interventions in one of the most challenging neurological disorders.
Circular Genomics calls for those interested in advancing understanding of Alzheimer's to engage with their presentation at CTAD 2025, as this research signifies a pivotal moment in the journey towards improving diagnosis and treatment strategies for Alzheimer’s Disease.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.